If you would like to order a Child Safety Kit, please complete the following registration form.

State *  
State License # * 
First Name * 
Last Name * 
Mailing Address * 
Address 2  
City * 
State *  
ZIP Code * 
Phone Number * 
E-mail Address * 
* 
Name of Practice   (if applicable)
 How many kits?
 

By clicking this “Submit Form” button, I confirm that I am 18 years of age or older and I consent to the terms of the Cephalon Privacy Policy.
  

Privacy statement

Your privacy is important. The information you give us will be used by Cephalon in accordance with our Privacy Policy. Click here to view our Privacy Policy


Important Safety Information

WARNING: IMPORTANCE OF PROPER PATIENT SELECTION, DOSING, and POTENTIAL FOR ABUSE

Reports of serious adverse events, including deaths in patients treated with ACTIQ have been reported. Deaths occurred as a result of improper patient selection (e.g., use in opioid non-tolerant patients) and/or improper dosing. The substitution of ACTIQ for any other fentanyl product may result in fatal overdose.

ACTIQ is indicated only for the management of breakthrough cancer pain in patients with malignancies who are already receiving and who are tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain. Patients considered opioid tolerant are those who are taking around-the-clock medicine consisting of at least 60 mg of oral morphine daily, at least 25 mcg of transdermal fentanyl/hour, at least 30 mg of oral oxycodone daily, at least 8 mg oral hydromorphone daily, at least 25 mg oral oxymorphone daily, or an equianalgesic dose of another opioid for a week or longer.

ACTIQ is not indicated for use in opioid non-tolerant patients including those with only as needed (PRN) prior exposure.

Life-threatening respiratory depression could occur at any dose in opioid non-tolerant patients. Deaths have occurred in opioid non-tolerant patients.

ACTIQ is contraindicated in the management of acute or postoperative pain including headache/migraine.

When prescribing, do not convert patients on a mcg per mcg basis to ACTIQ from other fentanyl products.

When dispensing, do not substitute an ACTIQ prescription for other fentanyl products. Substantial differences exist in the pharmacokinetic profile of ACTIQ compared to other fentanyl products that result in clinically important differences in the extent of absorption of fentanyl. As a result of these differences, the substitution of ACTIQ for any other fentanyl product may result in fatal overdose.

Special care must be used when dosing ACTIQ. If the breakthrough pain episode is not relieved 15 minutes after completion of the ACTIQ unit, patients may take ONLY ONE additional dose using the same strength and then must wait at least 4 hours before taking another dose [see Dosage and Administration (2.2)].

ACTIQ contains fentanyl, an opioid agonist and a Schedule II controlled substance, with an abuse liability similar to other opioid analgesics. ACTIQ can be abused in a manner similar to other opioid agonists, legal or illicit. This should be considered when prescribing or dispensing ACTIQ in situations where the physician or pharmacist is concerned about an increased risk of misuse, abuse or diversion. Schedule II opioid substances which include morphine, oxycodone, hydromorphone, oxymorphone, and methadone have the highest potential for abuse and risk of fatal overdose due to respiratory depression.

Patients and their caregivers must be instructed that ACTIQ contains a medicine in an amount which can be fatal to a child. Death has been reported in children who have accidentally ingested ACTIQ. All units must be kept out of the reach of children and opened units properly discarded [see Warnings and Precautions (5.3), Patient Counseling Information (17.5, 17.6), and How Supplied/Storage and Handling (16.2)].

ACTIQ is intended to be used only in the care of cancer patients and only by oncologists and pain specialists who are knowledgeable of and skilled in the use of Schedule II opioids to treat cancer pain.

The concomitant use of ACTIQ with strong and moderate cytochrome P450 3A4 inhibitors may result in an increase in fentanyl plasma concentrations, and may cause potentially fatal respiratory depression [see Drug Interactions (7)].

Because of the risk for misuse, abuse, addiction, and overdose, ACTIQ is available only through a restricted distribution program, required by the Food and Drug Administration, called the ACTIQ REMS Program (Risk Evaluation and Mitigation Strategy). Under the ACTIQ REMS Program, healthcare professionals (who prescribe to outpatients), as well as outpatients, pharmacies and distributors must enroll in the program to prescribe, receive, dispense, and distribute ACTIQ, respectively. [See Warnings and Precautions (5.10)] Further information is available at www.actiqandfentorarems.com or by calling 1-888-688-6885.

Indication: ACTIQ is an opioid analgesic indicated only for the management of breakthrough cancer pain in patients 16 and older with malignancies who are already receiving and who are tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain. Patients must remain on around-the-clock opioids when taking ACTIQ.

The following is not a complete list; please see full prescribing information.

Contraindications:

  • ACTIQ must not be used in opioid non-tolerant patients because life-threatening respiratory depression and death can occur at any dose in opioid non-tolerant patients
  • ACTIQ is contraindicated in the management of acute or postoperative pain including headache/migraine and dental pain
  • ACTIQ is contraindicated in patients with known intolerance or hypersensitivity to any of its components or the drug fentanyl

Warnings and Precautions:

  • Clinically significant respiratory and CNS depression can occur. Monitor patients accordingly
  • Full and partially consumed ACTIQ units contain medicine that can be fatal to a child. Ensure proper storage and disposal. Interim safe storage container available (“ACTIQ Child Safety Kit”)
  • Use with other CNS depressants and cytochrome P450 3A4 inhibitors may increase depressant effects including respiratory depression, hypotension, and profound sedation. Consider dosage adjustments if warranted
  • Titrate ACTIQ cautiously in patients with chronic obstructive pulmonary disease or preexisting medical conditions predisposing them to respiratory depression
  • Administer ACTIQ with extreme caution in patients susceptible to intracranial effects of CO2 retention
  • ACTIQ is available only through a restricted distribution program called the ACTIQ REMS Program

Adverse Reactions:

  • Most common adverse reactions during titration phase (frequency ≥5%): nausea, dizziness, somnolence, vomiting, asthenia, and headache. Most common additional adverse reactions during longer-term treatment (frequency ≥5%): dyspnea, constipation, anxiety, confusion, depression, rash, and insomnia.

Postmarketing Experience:

  • Postmarketing reports of dental decay of varying severity including dental caries, tooth loss, and gum line erosion have been received in patients taking ACTIQ

Drug Interactions:

  • Monitor patients who begin therapy with, or increase dose of inhibitors of CYP 3A4, for signs of opioid toxicity
  • Monitor patients who stop therapy with, or decrease dose of, inducers of CYP 3A4, for signs of opioid toxicity

Use in Specific Populations:

  • Safety and effectiveness in pediatric patients below 16 years of age have not been established
  • Administer ACTIQ with caution to patients with liver or kidney dysfunction

Please see accompanying full prescribing information, including boxed warning.